- Butantan-DV is a dengue vaccine made in Brazil.
- Anvisa approved it on 26 November.
- It is for people aged 12 to 59 years.
- The vaccine needs only one dose to work.
- One dose can help reach remote Amazon communities.
- Trials in Brazil had 16,000 volunteers over nearly a decade.
- The vaccine showed 74.7% overall and 91.6% severe efficacy.
- More than 1,000,000 doses are ready for distribution.
- It will join the national programme in early 2026.
Difficult words
- vaccine — medicine that helps the body avoid disease
- approved — to say yes to a new medicine
- dose — small amount of medicine for one timedoses
- remote — far away from towns and cities
- Trials — study to test a medicine or vaccine
- volunteers — person who joins a study by choice
- efficacy — how well a medicine or vaccine works
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you take a vaccine that needs one dose?
- Have you visited a remote area?
Related articles
Low-cost cooling could help Bangladesh garment workers
A University of Sydney study, published in The Lancet Planetary Health on Monday (20 October), tested simple low-cost cooling in a chamber that mimicked extreme factory heat. Fans and water partly restored productivity; a reflective roof cut indoor temperature by 2.5°C.
Few new antibiotics for children amid rising resistance
Global experts warn that few child-friendly antibiotics are being developed while antimicrobial resistance already causes millions of deaths. A 2026 Benchmark finds fewer drugs in company pipelines and a shortage of medicines for under-five children.
AI coach helps medical students learn suturing
Researchers at Johns Hopkins developed an explainable AI tool that gives immediate text feedback to medical students practicing suturing. A small randomized study found faster learning for students with prior experience; beginners showed less benefit.
